Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.
| Status: | Completed |
|---|---|
| Conditions: | Liver Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 9/28/2017 |
| Start Date: | September 2007 |
| End Date: | December 2013 |
Assessment of Liver Cancer Response to Transcatheter Arterial Chemoembolization (TACE) Using Functional Triple-Phase MultiHance-Enhanced Magnetic Resonance Imaging (MRI)
This research is being done to find out if using the contrast agent MultiHance can be used to
show how a liver tumor responds to the chemotherapy given during Transcatheter Arterial
Chemoembolization (TACE).
show how a liver tumor responds to the chemotherapy given during Transcatheter Arterial
Chemoembolization (TACE).
MultiHance is approved by the Food and Drug Administration (FDA) for use as a contrast
material for Magnetic Resonance Imaging (MRI) scans of the central nervous system. It is
believed that using MultiHance may be able to help doctors tell normal liver cells apart from
active tumor and from tumor affected by the chemotherapy. In this way, MultiHance may improve
the way patients with hepatocellular carcinoma are managed clinically.
We hypothesize that the Multi-Hance contrast material will provide better image definition of
treated liver tumor(s) on MRI imaging in comparison to other commercially available contrast
agents.
material for Magnetic Resonance Imaging (MRI) scans of the central nervous system. It is
believed that using MultiHance may be able to help doctors tell normal liver cells apart from
active tumor and from tumor affected by the chemotherapy. In this way, MultiHance may improve
the way patients with hepatocellular carcinoma are managed clinically.
We hypothesize that the Multi-Hance contrast material will provide better image definition of
treated liver tumor(s) on MRI imaging in comparison to other commercially available contrast
agents.
Inclusion Criteria:
- Outpatients between the ages of 18 - 80 seen in the cardiovascular and interventional
radiology clinic who are scheduled for TACE.
- International Normalized Ratio (INR) <1.4
- Platelet count > 80,000
Exclusion Criteria:
- Contraindications to TACE procedure
- Unable to have an MRI Scan
- Allergy or hypersensitivity reactions to gadolinium or any other ingredients,
including benzyl alcohol
- Patients with sickle cell anemia , hemoglobinopathies and other hemolytic anemias
- Known clinical hypersensitivity or a history of asthma or allergic respiratory
disorders
- Patients with advanced renal failure (those currently requiring dialysis or with a
Glomerular Filtration Rate<15cc/min)
- Pregnancy
We found this trial at
1
site
Johns Hopkins Hospital Patients are the focus of everything we do at The Johns Hopkins...
Click here to add this to my saved trials
